Microgel Technology Scales For Adult Blood Clotting
Researchers have developed a microgel particle decorated with a peptide that allows it to bind to fibrin at sites of injury. Scientists are currently working on scaling the technology for use in adult patients. The development may eventually serve as an alternative to traditional blood transfusions. The product may specifically assist in regions facing limitations in blood stockpiles and transport capabilities. This development follows previous work on specialized designs for neonatal care. Animal models show a 50-60% decrease in bleeding compared to controls, and the technology is being scaled for adult use. Current work focuses on ensuring the product works effectively with adult samples. The ultimate goal is to replace the need for blood transfusions entirely. Professor Ashley Brown and Matt Fox are leading the research efforts.
Topics
Developing
- 862d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 862d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 862d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 862d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
“decorate it with a peptide that allows for the microgel particle to. bleeding and injury because we have put peptide on the surface of the particle that allows it to bind to fibrin at sites of injury.”
“So we've tested the material both in human samples in the lab as well as in a mouse model of bleeding as well. So what we've found in the human samples in the lab, we found this material to be quite effective in samples that are collected from neonatal samples.”
“we have put peptide on the surface of the particle that allows it to bind to fibrin at sites of injury. So how effective is this material?”
“we have put peptide on the surface of the particle that allows it to bind to fibrin at sites of injury.”
“We have also seen in the animal model that we can decrease bleeding after an injury by 50 to 60 percent compared to controls.”
“we have tested the material both in the lab in human plasma samples. So plasma is blood without the cellular component. So we've tested the material both in human samples in the bleeding and injury”
“we found this material to be quite effective in samples that are collected from neonatal samples. have tested the material both in the lab in human plasma samples.”
“it's designed more specifically to help clotting in babies, but my lab has also developed versions of this technology that work quite well with adult samples”
“we have been working on scaling that technology up specifically to be used in adult patients.”
“This product could make a really big difference when there are low stocks of blood.”
“when there are low stocks of blood. So that's a pretty perfect”
“But my lab has also developed versions of this technology that work quite well with adult samples. And we have been working on scaling that technology up specifically.”
“this product could absolutely make a difference. I will future, what kind of difference could this make? I don't know, in places where perhaps stocks of donated blood are low.”
“And we have been working on scaling that technology up specifically.”
“Our ultimate goal would be to replace blood and have this be as a complete alternative.”
“Our ultimate goal would be to replace blood and have this be as a complete alternative. We have been working on scaling that technology up specifically to be used in adult patients.”
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade